OOIR: Observatory of International Research

Papers

(The median citation count of Parkinsonism & Related Disorders is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Cerebello-thalamofrontal dysconnectivity in paroxysmal kinesigenic dyskinesia: A resting-state fMRI study	109
Hemiatrophy-hemiparkinsonism and Poland syndrome: A causative or coincidental association?	74
Fear among patients with Parkinson's disease and repeated falls: Analysis of skin conductance responses during simulated accidents	64
Apomorphine sublingual film for “OFF” episodes in Parkinson’s disease: analysis of baseline factors	62
Leigh-like syndrome as a presentation of biallelic variants in DNAJC30 gene with predominant putamen degeneration and limb dystonia	60
Critical Appraisal of Economic Evaluation of Biomarkers Used for Screening of Dementia	57
A novel summary index derived from Kinect to evaluate the severity of postural abnormalities in patients with Parkinson’s Disease	56
Early onset hemichorea-parkinsonism with POLG mutation without external ophthalmoplegia responsive to pallidal DBS	54
White matter connectivity networks predict early dementia conversion in Parkinson’s disease	52
Examination of cognitive function in Parkinson's disease patients with chronic kidney disease	52
Association of Baseline Serum Urate Levels with Longitudinal General Cognition in Non-Demented Parkinson's Disease	49
Chorea-Acanthocytosis: A Case Report	46
Association and Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson’s Disease–related Cognitive Impairment	44
“Pop-up” studies: Observational studies in Huntington disease conducted at annual family convention	44
Role of linagliptin, a dipeptidyl peptidase-4 inhibitor against oxidative stress and neuronal damage in experimental diabetic aging brain of female rats of different age groups.	44
Targeting sedentary behavior decreases depressive symptoms and improves sleep in people with Parkinson’s Disease	40
Fibrinogen exacerbates GCase ubiquitination via ATF5-induced TRIP12 activation in Parkinson's Disease	36
β-Caryophyllene decreases neuroinflammation and exerts neuroprotection of dopaminergic neurons in a model of hemiparkinsonism through inhibition of the NLRP3 inflammasome	35
Association between serum lipid levels and dopamine loss in idiopathic rapid eye movement sleep behavior disorder	35
Longitudinal brain changes in Parkinson's disease with severe olfactory deficit	34
Is rapid eye movement sleep behavior disorder a marker of Parkinson's disease severity?	33
Perry disease in an Argentine family due to the DCTN1 p.G67D variant	33
Relation between Clinical and Electrophysiological Correlates of Peripheral Polyneuropathy and Oral Levodopa Treatment in People with Parkinson’s Disease	32
Integrity of Dopaminergic Terminals in the Caudate Nucleus Modulates Rest Tremor in Parkinson’s Disease	31
Digital devices and wearable technology for quantification of freezing of gait in adolescents with pediatric movement disorders attending school	31

Objective sleep enhancement in Parkinson's disease: A sham-controlled trial of low-frequency repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex	30
Treatment of refractory post-hypoxic myoclonus and focal epilepsy with subthalamic nuclei deep brain stimulation	30
Bilateral Hemimasticatory spasm in a patient with hypereosinophilic syndrome	30
A useful cognitive motor dual task paradigm in prodromal and manifest Huntington’s disease	29
Magnetic resonance spectroscopy reveals evidence of brain oxidative stress in Tourette syndrome	27
Diet quality and prodromal Parkinson's disease probability in isolated REM sleep behavior disorder	27
Evaluation of mild cognitive impairment in older patients with essential tremor	26
Psychometric analysis of the short form UCLA Loneliness Scale (ULS-8) in people with Parkinson's disease	26
Prevalence and clinical impact of alpha-synuclein pathology in idiopathic normal pressure hydrocephalus: Insights from RT-QuIC assay	26
Asymmetric Parkinsonism and Ataxia with autonomic dysfunction and RBD	26
The effects of stretching in Parkinson's disease: A systematic review of randomized controlled trials	26
Cognitive impairment in REM-sleep behaviour disorder and individuals at risk of Parkinson's disease	25
Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?	25
Malignant Neuroleptic Syndrome in a Patient with Huntington's Disease	25
Retinal microvascular impairment in Parkinson's disease with cognitive dysfunction	25
Dual Phase 18F-FP-CIT PET in presynaptic and trans-synaptic nigrostriatal dysfunction in Multiple System Atrophy	24
Leveraging Telehealth and Wearables for Parkinson’s Disease: Innovative Approaches to Enhance Personalized Care	24
A case of probable Progressive Supranuclear Palsy Frontal type (PSP-F) presenting as psychosis	24
Error-based biofeedback for gait training in Parkinson's disease	24
Neurocognition, Cerebellar Functions and Psychiatric Features in Spinocerebellar Ataxia Type 34	23
Effects of an intensive, multidisciplinary rehabilitative treatment in an outpatient setting on clinical outcomes in Parkinson’s Disease: preliminary results.	23
Early-onset Parkinson's disease, regional and national burden, and its attributable risk factors in 204 countries and regions from 1990 to 2021: Results from the global burden of disease study 2021	23
FindPD.DaT: Development of a Novel Artificial Intelligence-driven Tool for Diagnosis of Parkinson’s Disease using Dopamine Transporter Scans	23
Effect of ND0612 Continuous Infusion on Motor Performance and Experiences of Daily Living in Patients With Parkinson’s Disease	23
Perioperative quantification of MDS-UPDRS-III tremor measurements in patients with Parkinson’s Disease using accelerometry	22
APOE carrier status and cognitive outcomes after STN-DBS surgery for Parkinson’s disease.	22
Diagnosis of vascular parkinsonism: A new tool for gait hypokinesia occurring in older persons	21
Postural abnormalities in Asian and Caucasian Parkinson's disease patients: A multicenter study	21
Mitochondrial and autophagic dysfunctions of skin fibroblasts derived from pantothenate kinase-associated neurodegeneration patients carrying PANK2 mutations and the rescuing effects of allantoin	21
Associations of cerebrospinal fluid monoamine metabolites with striatal dopamine transporter binding and 123I-meta-iodobenzylguanidine cardiac scintigraphy in Parkinson's disease: Multivariate analyse	21
Establishing a framework for quality of inpatient care for Parkinson's disease: A study on inpatient medication administration	20
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum	20
Machine Learning Analysis of the Interaction Between miR-155 and LRRK2 Gene Variants in Parkinson's Disease Progression	19
Clinical Evaluation of Parkinson's Disease Patients Admitted to the Movement Disorders Outpatient Clinic of Istanbul Taksim Training and Research Hospital, Turkey, 2023	19
Huntington Disease – Update on Recent Advances and a Look Toward the Future	19
Unveiling the Complexity of Parkinson's Disease: Exploring Subtypes and Tracing its Five-Stage Natural Course	19
The Elevated Risk of Dementia in Parkinson's Disease Patients Associated with Metabolic Syndrome	19
Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study	19
Proteomic profile of saliva in patients with Parkinson's disease after the practice of interval exercise	18
The psychological correlates of fatigue in Parkinson's disease: Contribution of maladaptive metacognitive beliefs	18
Sex differences for cognitive decline in progressive supranuclear palsy	18
Association between global cognitive function and autonomic dysfunction in patients with de novo Parkinson’s disease	18
Parkinson’s Disease with Hyposmia and Dysautonomia: Does It Represent a Distinct Subtype?	18
Efficacy of Once-Daily Valbenazine in Adults with Chorea Associated with Huntington’s Disease: Effect Size Over Time	18
A late-onset neurological disorder: Is progression inevitable? Expert Commentary	18
Atypical antipsychotic use and mortality risk in Parkinson disease	18
Tardive dyskinesia versus tardive syndrome. What is in a name?	18
Carrier Mediated Delivery System Bearing Dopamine for Effective Management of Parkinsonism	18
Establishing exercise habits in patients with Parkinson's disease through an exercise group model	18
Study of 17β estradiol with neuropeptide and amyloid beta fragment on neuronal and biochemical functions in naturally menopausal aging rats	18

Hereditary Spastic Paraparesis with SPG6 mutation: First case report from Malaysia	18
From writer's cramp to blepharoclonus: An atypical journey with a novel KMT2B variant	18
Alterations in electrochemical skin conductance as a marker of autonomic dysfunction in multiple system atrophy	18
Somnolence-Related Events Over Time During Valbenazine Treatment for Chorea Associated with Huntington’s Disease	18
The role of neurotrophic factors in development Parkinson's disease dementia	18
The characteristic and prognostic role of blood inflammatory markers in patients with Huntington's disease from China	18
Editorial Board	17
The MemTrax memory test for detecting and assessing cognitive impairment in Parkinson's disease	17
Wearable sensors for assessing disease severity and progression in Progressive Supranuclear Palsy	17
Atypical Presentation of Autosomal Recessive Cerebellar Ataxia Type I Mimicking Amyotrophic Lateral Sclerosis	17
Efficacy and safety of high doses of safinamide in advanced Parkinson disease	17
Impact of inpatient mobility on outcomes in Parkinson's disease	17
Dentate calcifications with palatal tremor and facial myorhythmia in adult-onset Cerebral X-linked Adrenoleukodystrophy	17
Frequency settings of subthalamic nucleus DBS for Parkinson's disease: A systematic review and network meta-analysis	17
Editorial Board	16
Editorial Board	16
Long-term incobotulinumtoxinA treatment for chronic sialorrhea: efficacy and safety over 64 weeks	16
Genetic study of early-onset Parkinson's disease in the Malaysian population	16
Gerstmann-Straussler-Scheinker disease: Lessons from two new Indian kindreds	16
Cognitive and neuropathological contributions to gait dysfunction in Parkinson's disease	16
Brittle dyskinesias after bilateral STN DBS: dissociation of microlesioning effect on tremor versus on dyskinesias	16
Editorial Board	16
Commentary on “The use of hypoglycemic drugs in Parkinson's disease: An updated meta-analysis of randomized controlled trials”	16
Machine Learning-based World Health Organization Disability Assessment Schedule for persons with Parkinson's disease	16
Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: A systematic review and meta-analysis	16
Differences in progressive supranuclear palsy in patients of Asian ancestry?	16
¿It Is Any Difference Between Directional Vs Omnidirectional Lead For Treatment In Parkinson Disease?	16
The distinctive functional connectivity of the cholinergic nucleus basalis of Meynert in Parkinson’s disease across different cognitive status	16
Single-dose intranasal administration of α-syn PFFs induce lewy neurite-like pathology in olfactory bulbs	16
Augmented reality cueing for freezing of gait: Reviewing an emerging therapy	16
A young man with progressive dysarthria, generalized slowness and memory loss	15
Genetic overlap between dystonia and other neurologic disorders: A study of 1,100 exomes	15
Dopaminergic dysfunctions instigated by Nano-formulation of Neonicotinoid pesticides in mice	15
Motor and non-motor responses of STN DBS in early onset PLA2G6 related Parkinsonism with compound heterozygous mutation from China	15
Cystatin C as a Biomarker for the Development of Parkinson disease in Patients with Chronic Kidney Disease	15
Protective Lifestyle Risk Factors Against Parkinson’s Disease In Sub-Saharan Africa: A Review On Current Evidence	15
Effect of Safinamide on Non-motor symptoms and QoL According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose	15
Expanding the phenotypic and genotypic spectrum of DYT-TUBB4A with seven patients from India	15
Colony-Stimulating Factor-1 Receptor-Related Disorders in the Hispanic Population: A Report of six Families	15
Functional movement disorders in dopa-responsive dystonia	15
A de novo GRIA3 variant with complex hyperkinetic movement disorder in a girl with developmental delay and self-limited epilepsy	15
On demand inhaled levodopa in Parkinson´s disease (pd) patients with device assisted therapies	15
The BEACON Study: LRRK2 inhibition by BIIB122/DNL151 in participants with Pathogenic LRRK2 Variants and Parkinson’s disease	15
Association of bilateral oophorectomy with incidence of Parkinson's disease: A systematic review and meta-analysis	14
Segmental dystonia as the prominent phenotype resulting from a MICU1 splice variant in a new Indian case	14
Levodopa, homocysteine and Parkinson's disease: What's the problem?	14
Phenotypic manifestations of KIF5A Arg1007Lys mutation: A large kindred study	14
The impact of anti-inflammatory therapy on Parkinson's disease incidence: A retrospective cohort study	14
Distractibility predicts favourable response of functional tremor to transcranial magnetic stimulation: An electrophysiological study	14
Predictors of multi-domain cognitive decline following DBS for treatment of Parkinson's disease	14
Effect of eight-week online cognitive training in Parkinson's disease: A double-blind, randomized, controlled trial	14
Personality assessment with Temperament and Character Inventory in Parkinson's disease	14
Diagnostic performance of T1-Weighted MRI gray matter biomarkers in Parkinson's disease: A systematic review and meta-analysis	14
MRI index of glymphatic system mediates the influence of locus coeruleus on cognition in Parkinson's disease	14
Comment on “Defining ‘OFF’ time in device-aided therapy criteria for Parkinson's disease: Gaps and opportunities”	13
Ethnoracial differences for caregiving burden in Parkinson’s disease	13
Transcranial high-intensity Magnetic Resonance-guided focused ultrasound (tcMRgFUS) – safety and impacts on tremor severity and quality of life	13
The factors for choosing intesticular gel therapy	13
Seronegative basal ganglia encephalitis mimicking dementia of Lewy body	13
Identification of the needs of patients with Parkinson’s disease through a qualitative research process	13
Evaluating motor progression of juvenile-onset Huntington's Disease: An Enroll-HD analysis	13
Subjective cognitive complaints are important in PD-MCI criteria: Associations with CSF markers and cognitive decline	13
Introducing Virtual Shared Medical Appointments as a Novel Treatment Platform for Functional Movement Disorders	13
Post-COVID parkinsonism: A scoping review	13
Analysis of GIPC1 CGG repeat expansions in essential tremor	13
The role of semispinalis capitis muscles in cervical dystonia with goose-neck posture	13
Empowering the management of early-onset Parkinson’s disease: The role of technology	13
MRgFUS of the nucleus ventralis intermedius in essential tremor modulates functional connectivity within the classical tremor network and beyond	13
Mitochondrial Membrane Protein-Associated Neurodegeneration (MPAN) Presenting With Parkinsonism Findings: A Case Report	13
Expanding the genotype-phenotype landscape of PDE10A-associated movement disorders	13
Association between global cognitive function and autonomic dysfunction in patients with de novo Parkinson’s disease	13
Response to levodopa in Parkinson's disease over time. A 4-year follow-up study	12
Dopaminergic connectivity reconfiguration in the dementia with Lewy bodies continuum	12
Recent advances in non-Huntington's disease choreas	12
Tongue strength in progressive supranuclear palsy	12
Thyroid disease in cervical dystonia	12
Attainment of physiologic salivary flow rate with long-term incobotulinumtoxinA treatment for sialorrhea in Parkinson’s disease and other neurologic conditions	12
The use of hypoglycemic drugs in Parkinson's disease: An updated meta-analysis of randomized controlled trials	12
Real-world effect of age on long-term effectiveness and safety of levodopa-carbidopa intestinal gel: post hoc analysis from the DUOGLOBE study	12
Grey matter correlates of dystonic soft signs in essential tremor	12

Motor band sign in a Huntington disease phenocopy	12
Tremor is associated with familial clustering of dystonia	12
Cerebellar blood perfusion is a diagnostic, but not a prognostic, marker for parkinsonian-dominant type multiple system atrophy	12
Convergence insufficiency and Parkinson's disease progression	12
Reliability of remote video ratings of the scale for assessment and rating of ataxia	12
Cropland associated with risk of Parkinson's disease in the northern Great Plains	12
A case of treatable encephalopathy, developmental regression, and proximal tremor: Expert commentary	12
Interaction between caffeine intake and polymorphisms of PARK16 modifies Parkinson’s Disease risk	12
Sexual dysfunction in patients with focal dystonia	12
“A man with an arched back”: Expert commentary	12
Increased blood-derived mitochondrial DNA copy number in African ancestry individuals with Parkinson's disease	12
Late-onset parkinsonism in a patient with a novel frameshift THAP1 variant	12
Spinocerebellar ataxia subtype 40: Report of a case and review of literature	12
Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease	12
Cognitive function, psychobehavioral symptoms, and MRI features in patients with non-demented Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies	12
The effects of once-daily opicapone 50 mg on the pharmacokinetics of levodopa administered as carbidopa/levodopa extended-release capsules: an open-label study	12
The feasibility of using loss of “swallow tail sign” on 3T – susceptibility weighted MRI in diagnosis of Parkinson’s disease	12
Sweet as Parkinson's disease: Rethinking the impact of diabetes mellitus	12
Improvement of non-motor symptoms with NE3107 adjunctive to Carbidopa / Levodopa in patients with Parkinson`s disease: A Phase 2A, placebo-controlled study	12
TorsinA-interacting protein 2 (TOR1AIP2) variants in an autosomal dominant combined dystonia-hemichorea-hemiballismus syndrome in two families	11
REM density in Parkinson’s disease: Effects of motor, cognitive, and autonomic function, and the impact of evening dopaminergic medication	11
Longitudinal evaluation of patients with isolated head tremor	11
ERCC4 variants causing neurodegeneration with ataxia and chorea in three siblings in Lithuanian family	11
WITHDRAWN	11
Structural and functional brain abnormalities in idiopathic cervical dystonia: a multimodal meta-analysis	11
Usage of modern technologies like VR therapy, physio therapy along with levodopa in Young-Onset Parkinson's disease patients	11
Development of a screening AI model for Parkinson's disease using gait image sequences	11
Continuous subcutaneous levodopa/carbidopa infusion with ND0612 for Parkinson’s disease: Three-year data from the open-label BeyoND study	11
The use of botulinum toxin A in the treatment of hand tremor	11
Correcting Vertical Perception to Reverse Pisa Syndrome in Parkinson’s Disease: A Case Report	11
Patients with progressive supranuclear palsy need to be seen sooner and more frequently	11
Profile of patients with advanced Parkinson’s disease treated with Levodopa–entacapone–carbidopa intestinal gel (LECIG)	11
Challenges during prayer (namaz/salah) rituals in Muslim patients with Parkinson’s disease	11
Magnetic Resonance Imaging Marker for the Conversion from Idiopathic Late-onset Cerebellar Ataxia to Multiple System Atrophy	11
A challenging case of cerebellar ataxia associated with oro facial dominant chorea	11
Exposure factors and clinical characteristics associated with Parkinson's disease in GBA1 variant carriers: A Chinese GBA1-PD intrafamilial survey	11
A structural perspective on the interaction between glucocerebrosidase and the positive allosteric modulator BIA 28-6156	11
Calcium channel blockers and Parkinson's disease: A systematic review and meta-analysis	11
Sex differences in the association between nonalcoholic fatty liver disease and Parkinson's disease	11
Neuropsychological studies in children with tic hyperkinesis	11
Fecal tyrosine decarboxylase and motor response complications in Parkinson's disease	11
An atypical case of head tremor	11
Editorial Board	11
Opicapone Effect on Sleep Disorders in Fluctuating Parkinson’s Disease Patients: Findings from the OASIS Trial	11
Accelerometric quantification of MDS-UPDRS bradykinesia measurements in PD patients: A pilot study	11
Right to the Point - A Writer’s Cramp Successful Treatment	11
Resting-state EEG predicts cognitive decline in a neuropathologically diagnosed longitudinal community autopsied cohort	10
A case of levodopa responsive parkinsonism due to methanol toxicity, an impact of COVID-19 crisis	10
Development of osteomyelitis after COVID 19 in patients with vascular parkinsonism	10
A randomized clinical trial of candesartan for cognitive impairment in Parkinson's disease	10
Diagnosis across a cohort of “atypical” atypical and complex parkinsonism	10
Structural and functional connectomics of the olfactory system in Parkinson's disease: a systematic review	10
Utility of clinical tests for asymmetry in Parkinson's disease and Atypical Parkinsonian disorders: the PARK-SYMM scale study.	10
Enhanced low beta activity in Park2-associated Parkinson’s disease	10
Leucine-rich repeat kinase2 (LRRK2) associated Parkinson's disease: less vulnerable during Covid-19 pandemic?	10
Double blind, nonrandomized crossover study of active recharge biphasic deep brain stimulation for primary dystonia	10
Preliminary verification of a Kinect-based system for evaluating postural abnormalities in patients with Parkinson’s disease	10
Cerebral microbleeds in dementia with Lewy bodies	10
The iNPH Radscale May Better Predict Whether Ventriculoperitonal Shunting was Offered, Compared to Drain Trial Gait Variables	10
Exploring Novel Therapeutic Approaches in Parkinson’s Disease: A Comprehensive Review	10
Backward leaning during gait: An underrecognized sign in Niemann-Pick type C	10
A relatively common hypomorphic variant in WARS2 causes monogenic disease	10
Comparison of voice parameters, self-assessment of speech and sialorrhea levels in Parkinson's disease patients with and without swallowing problems	10
Long-term safety of continuous levodopa/carbidopa infusion with ND0612: results from the ongoing BeyoND study	10
Non-pharmacological rehabilitation for people living with advanced Parkinson's disease: A scoping review of interventions	10
An immersive virtual reality shopping task detects declines in instrumental activities of daily living in individuals with Parkinson's disease	10
Assessment of Cerebral Cortical Atrophy Using Visual Rating Scale in Patients with Functional Movement Disorder	10
Plasma sphingolipids, dopaminergic degeneration and clinical progression in idiopathic Parkinson's disease	10
Editorial Board	9
Functional movement disorder comorbidity in Parkinson's disease: A multicenter descriptive study	9
A case of treatable encephalopathy, developmental regression, and proximal tremor	9
Are we ready for automated deep brain stimulation programming?	9
Symptom changes with hormonal variations in genetic dystonia	9
Developing a Female-Specific Mouse Model for Parkinson’s Disease Using a High-Sensitivity Neural Network	9
A benign course of Parkinson's disease associated with different mutations in the glucocerebrosidase gene – A case series	9
Inter-muscular coherence in speed skaters with skater's cramp	9
Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies	9
A multidisciplinary telemedicine approach for managing frailty in Parkinson's disease. A longitudinal, case-control study	9
Clinical correlations of cerebrospinal fluid biomarkers including neuron-glia 2 and neurofilament light chain in patients with multiple system atrophy	9
A novel GNAL pathogenic variant leading to generalized dystonia: Immediate and sustained response to globus pallidus internus deep brain stimulation	9
MOBP gene risk variant is associated with higher cerebrospinal fluid levels of neurofilament light chain: a Barcelona PSP Registry study	9
Real world evidence of efficacy ad safety of subcutaneus foslevodopa/foscarbidopa infusion in advanced Parkinson disease	9
Parkinson's disease patients with absence of normal dipping status were more vulnerable to cognitive impairment from the early stages	9
Efficacy of Probiotics for treatment of constipation in Parkinson’s patients: a systematic review and meta-analysis	9
High preoperative gait variability is a prognostic predictor of gait and balance in Parkinson disease patients with deep brain stimulation	9
Other clinical uses for apomorphine: Sedation and sleep disorders, withdrawal of oral dopaminergic medication, palliative care, restless legs syndrome, traumatic brain injury, sexual dysfunction	9
Monocyte to high-density lipoprotein cholesterol ratio reflects the peripheral inflammatory state in parkinsonian disorders	9
Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease	9
tDCS application for postural control in Parkinson's disease: Effects are associated with baseline characteristics	9
Influence of Toxic Exposure on the Age of Onset of Parkinson's Disease: An Observational and Analytical Study.	9
Clinical progression of vascular Parkinsonism in ischemic stroke patients with metabolic syndrome	9
TMS-evoked potentials provide novel neurophysiological features of Tourette syndrome	9
Multiple system atrophy like presentation with hot-cross bun sign in anti-IgLON5 disease	9
Nigrostriatal dysfunction in RFC1-related disorder/CANVAS	9
Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy	9